• Explore /
  • Poster
  • / Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Abstract Video & Slides Poster

Authors

null

Deepti Behl

Sutter Sacramento Medical Center, Sacramento, CA;

Deepti Behl , Michael Rothe , Pam K. Mangat , Elizabeth Garrett-Mayer , Laura Catherine Farrington , Oxana V. Crysler , Elie G. Dib , Herbert Leon Duvivier , Michael J. Hall , John Stuart Salmon , Olatunji B. Alese , Alissa S. Marr , Isa Ngirailemesang , Latha Polavaram , Ramya Thota , Eddy Shih-Hsin Yang , Raegan O'Lone , Gina N. Grantham , Susan Halabi , Richard L. Schilsky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02693535

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 122)

DOI

10.1200/JCO.2023.41.4_suppl.122

Abstract #

122

Poster Bd #

F19

Abstract Disclosures

Similar Posters

First Author: Tareq Al Baghdadi

First Author: Gordan Srkalovic

First Author: Timothy Lewis Cannon

First Author: Jean L. Grem